The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy

Abstract
Summary An unambiguous and specific HPLC assay was used to determine the pharmacokinetics of 7-hydroxymethotrexate (7-OHMTX) following the administration of moderate-dose methotrexate (MTX) 100 mg·m-2 to 37 patients with advanced head and neck cancer. There was marked interpatient variation but patient exposure to 7-OHMTX was considerable. There was, however, no correlation between the amount of 7-OHMTX produced and either tumour response or patient toxicity.